Hvað þýðir "Hreinsa"?
Dýrið ber ekki stökkbreytinguna. Það mun ekki þróa sjúkdóminn og mun ekki gefa það áfram.
Hundur Hörnun hunda í mörgum kerfum í Kerry Blue Terrier (CMSD-KBT)
The Canine Multiple System Degeneration (CMSD) DNA test is essential for Kerry Blue Terrier owners to ensure their dogs' health. CMSD is a hereditary neurological disorder affecting coordination and movement in Kerry Blue Terriers. Early genetic testing helps identify carriers and affected dogs, enabling responsible breeding decisions. By using the CMSD DNA test, breeders can reduce the risk of passing this debilitating condition to future generations. This test provides accurate, reliable results, promoting the well-being of your Kerry Blue Terrier. Protect your dog’s health with the CMSD DNA test today. Regular screening supports a healthier, happier canine companion.
Skammstöfun: CMSD-KBT
Grein stökkbreyting: SERAC1 c.1536G>A
Erfðir: Autosomal víkjandi
Skammstöfun
CMSD-KBT
Athuguð tíðni
Klínísk alvarleiki
Klínísk flokkun
Taugasjúkdómar
Greind stökkbreyting
SERAC1 c.1536G>A
p.(Trp512*)
p.(Trp512*)
Erfðamáti
Autosomal víkjandi
Próf samantekt:
Canine Multiple System Degeneration (CMSD) is a genetic disorder affecting Kerry Blue Terriers, causing progressive neurological decline. A DNA test is available to identify carriers and affected dogs, helping breeders make informed decisions. Early detection through testing can prevent the spread of this debilitating condition within the breed. Responsible breeding practices rely on these genetic insights to maintain healthy Kerry Blue Terrier populations. Overall, the CMSD DNA test is a valuable tool for canine health management.
Fáanlegt úr pakkanum: Basic
Þetta DNA próf er innifalið frá pakkanum okkar Basic — og er líka hluti af pökkunum Basic, Standard, Advanced, Complete.
Skoða DNA prófunarpakka →Veldu pakkann sem passar best við ræktunar- eða heilsustefnu dýranna þinna.
Understanding Canine Multiple System Degeneration in Kerry Blue Terriers (CMSD-KBT)
Canine Multiple System Degeneration (CMSD) is a progressive neurological disorder that primarily affects Kerry Blue Terriers. This condition is characterized by the degeneration of multiple systems within the nervous system, leading to a range of debilitating symptoms that can significantly impact the quality of life of affected dogs.
Symptoms of CMSD-KBT
The symptoms of CMSD-KBT typically manifest in early to mid-adulthood, although the age of onset can vary. Common signs include balance problems, difficulty walking, and a general lack of coordination. As the disease progresses, affected dogs may exhibit muscle weakness, tremors, and a decline in overall mobility. In some cases, dogs may also experience changes in behavior, such as increased anxiety or a reluctance to engage in normal activities.
Pathophysiology of CMSD-KBT
The underlying cause of CMSD-KBT lies in genetic mutations that affect the nervous system's ability to function properly. These mutations lead to the degeneration of nerve cells, which in turn causes a breakdown of communication between the brain and the body. This disruption results in the clinical symptoms observed in affected dogs. Understanding the genetic basis of CMSD-KBT is crucial for breeders and owners, as it allows for informed decisions regarding breeding practices and the management of affected animals.
Management and Care for Affected Dogs
While there is currently no cure for CMSD-KBT, management strategies can help improve the quality of life for affected dogs. Regular veterinary check-ups are essential for monitoring the progression of the disease and addressing any health concerns that arise. Physical therapy and rehabilitation exercises can assist in maintaining mobility and strength. Additionally, providing a safe and supportive environment can help dogs cope with their symptoms and enhance their overall well-being.
Niðurstaða
Canine Multiple System Degeneration in Kerry Blue Terriers is a serious condition that requires attention from dog owners and breeders. By understanding the symptoms, underlying causes, and management strategies associated with CMSD-KBT, stakeholders can work towards improving the lives of affected dogs while making informed breeding decisions to reduce the prevalence of this condition in the breed.
Tegund viðurkennd fyrir prófið: Hörnun hunda í mörgum kerfum í Kerry Blue Terrier (CMSD-KBT)
- Kerry Blue Terrier
🧬 Interpretation of genotypes CMSD-KBT
Arfgerð
Staða
🟡 N/N
Ekki flutningsaðili - Engin áhætta
🟡 N/CMSD-KBT
Flutningsaðili - Engin áhætta
❌ CMSD-KBT/CMSD-KBT
Fyrir áhrifum - í hættu
Algengar spurningar: skilja túlkunina
Er „flutningsaðili“ alvara?
Nei. Dýrið er almennt heilbrigt en getur sent stökkbreytinguna til þess afkvæmi.
Hvað ef dýr hefur „áhrif“?
Það ber tvö stökkbreytt eintök. Búist er við klínískum einkennum eftir því sjúkdómnum. Það ætti ekki að rækta það.
Af hverju er munur á karli / konu?
Sumir sjúkdómar eru kyntengdir, þannig að tjáning þeirra er mismunandi eftir því kynlíf dýra.
Spáðu í afkvæmi
N/N (ekki-flutningsadili)
N/CMSD-KBT (Flytjandi)
CMSD-KBT/CMSD-KBT (Fyrir áhrifum)
Algengar spurningar um DNA próf
Hvað greinir þetta DNA próf?
This DNA test detects the mutation associated with Canine Multiple System Degeneration In Kerry Blue Terrier (CMSD-KBT) in order to identify clear, carrier, or at-risk animals.
Af hverju að prófa ræktunardýr?
DNA próf hjálpar ræktendum að skipuleggja öruggari pörun og draga úr hættu á að stökkbreytingin berist til afkvæma.
Hver er arfleifð þessa prófs?
Erfðastillingin sem tilkynnt er um fyrir þetta próf er Autosomal Recessive.
Hvaða stökkbreyting er greind í þessu prófi?
This test analyses the mutation SERAC1 c.1536G>A.
Er burðardýr endilega fyrir áhrifum?
Ekki endilega. Túlkun fer eftir erfðamynstri og arfgerðinni sem myndast.
Heimildir
Johnson GS, Mhlanga-Mutangadura T, Morava E, Kozicz T, Taylor JF, O’Brien DP, Schnabel RD. Canine Multiple System Degeneration is Associated with Distinct SERAC1 Mutations in Two Different Dog Breeds [abstract]. Presented at the 63rd Annual Meeting of the American Society of Human Genetics in Boston, Massachusetts; 2013 Oct 22-26.